International Journal of Clinical Research
International Journal of Clinical Research. 2024; 8: (10) ; 10.12208/j.ijcr.20240413 .
总浏览量: 149
湖北中医药大学附属天门市中医医院 湖北天门
*通讯作者： 甘浩东,单位：湖北中医药大学附属天门市中医医院 湖北天门；
目的 探讨重组人干扰素alb雾化吸入治疗小儿疱疹性咽峡炎价值分析。方法 取2023年1月-2024年1月我院疱疹性咽峡炎患儿作为研究对象（100例），由于患儿临床治疗方法存在差异，故将接受重组人干扰素alb雾化吸入者纳入研究组（50例），将接受常规治疗者纳入参照组（50例），对比两组治疗有效率、免疫功能指标、炎症因子水平等。结果 患儿治疗有效率对比，研究组高于参照组；患儿免疫功能指标对比，研究组高于参照组；患儿炎症因子水平对比，两组各项数据组间对比，存在明显差异，且研究组优于参照组（P＜ 0.05）。结论 小儿疱疹性咽峡炎临床应用重组人干扰素alb雾化吸入治疗的效果理想，可全面提高治疗有效率，增强患儿机体免疫功能，缓解炎性反应，有效促进康复，缩短症状恢复时间及住院时间，建议推广应用。
Objective To explore the value of recombinant human interferon alb atomization inhalation in the treatment of herpetic pharyngitis in children. Methods Children with herpetic pharyngitis in our hospital from January 2023 to January 2024 were selected as the research subjects (100 cases). Due to differences in clinical treatment methods for children, those who received recombinant human interferon alb atomization inhalation were included in the study group (50 cases), and those who received conventional treatment were included in the reference group (50 cases). The two groups were compared in terms of treatment effectiveness, immune function indicators, and inflammatory factor levels. Results The treatment effectiveness of the children was compared, and the study group was higher than the reference group; the immune function indicators of the children were compared, and the study group was higher than the reference group; the inflammatory factor levels of the children were compared, and there were significant differences between the two groups, and the study group was better than the reference group (P < 0.05). Conclusion The clinical application of recombinant human interferon alb atomization inhalation in the treatment of herpetic pharyngitis in children is ideal, which can comprehensively improve the treatment efficiency, enhance the immune function of children, relieve inflammatory response, effectively promote recovery, shorten the symptom recovery time and hospitalization time, and it is recommended to promote its application.
[1] 罗雪敏,黄东辉,邹晓惠. 馥感啉口服液联合重组人干扰素a1b治疗疱疹性咽峡炎的疗效及对患儿心肌酶谱和炎症因子的影响[J]. 海南医学,2022,33(10):1290-1293.
[2] 吴疑,熊必凤,王萍. 重组人干扰素a1b联合热毒宁治疗小儿疱疹性咽峡炎的临床疗效观察[J]. 全科口腔医学杂志（电子版）,2019,6(32):185,188.
[3] 韩琳,叶冰. 喉咽清口服液联合重组人干扰素a2b雾化对小儿疱疹性咽峡炎血清炎症因子及免疫功能的影响[J]. 中国医药科学,2024,14(8):100-104.
[4] 黄娜,祝伟,贾铷. 重组人干扰素1b和利巴韦林雾化吸入治疗小儿疱疹性咽峡炎的效果观察[J]. 中国实用医刊,2022,49(19):108-111.
[5] 潘家华,杨泽玉,潘家严,等. 重组人干扰素α2b口咽部喷雾治疗疱疹性咽峡炎的有效性和安全性多中心随机对照研究[J]. 中华实用儿科临床杂志,2020,35(4):279-284.
[6] 谭炳汪,曾志泉. 观察重组人干扰素α1b雾化吸人治疗疱疹性咽峡炎的疗效[J]. 家庭医药·就医选药,2020(5): 116-117.
[7] 靳宁超,胡青青,杨双杰. 重组人干扰素α2b联合阿昔洛韦对疱疹性咽峡炎患儿的治疗作用[J]. 华夏医学,2024, 37(4): 179-184.
[8] 李鑫,郑娟,王韵凌. 重组人干扰素α2b雾化吸入联合开喉剑喷雾剂治疗小儿疱疹性咽峡炎的疗效[J]. 临床合理用药,2023,16(12):136-138.
[9] 郑玉柏. 重组人干扰素α-2b雾化吸入治疗小儿疱疹性咽峡炎的临床效果分析[J]. 现代医学与健康研究（电子版）,2023,7(4):48-50.
[10] 叶国秀,周宝琴,马健,等. 重组人干扰素α2b雾化吸入联合利巴韦林喷雾剂治疗小儿疱疹性咽峡炎的临床效果[J]. 临床合理用药杂志,2021,14(31):100-102.